Articles

Find an Article

Filter articles

Applied Filters

Showing 31 to 40 of 45 results

Event preview: Life Sciences Patents Network Europe 2016

EU07-10-2016

On December 7, LSIPR will be hosting the Life Sciences Patents Network Europe 2016 at the Bloomsbury Hotel in London. Here we preview the main talking points.

Mind your language

Germany20-09-2016Bernd Allekotte and Markus Grammel

A decision by Germany’s Federal Court of Justice has developed the concept of the ‘doctrine of equivalents’, possibly benefiting pharma patent owners, say Bernd Allekotte and Markus Grammel of Grünecker.

Preview: Life Sciences IP Summit 2016

EU16-09-2016Sarah Porch

Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC.

IP in the digital age: a tricky path ahead for pharma companies?

EU13-09-2016Stephen Bennett, Elisabethann Wright, Mark Marfe and James Cross

The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins.

SPCs and the unitary patent system: what now?

EU, UK06-09-2016Christopher Stothers and Paul Abbott

Brexit will have significant consequences for the UK regarding SPCs and the unitary patent system, while the UPC’s proposed start date of early 2017 looks highly unlikely, say Christopher Stothers and Paul Abbott of Arnold & Porter.

Biomedical patents: the quest for balance

US18-08-2016Pat Carson and Mira Atanassova Mulvaney

The US Supreme Court’s Mayo and Myriad decisions have brought challenges to subject matter eligibility to the forefront in the biomedical industry, but they do not signal the end of biomedical patents. Pat Carson and Mira Atanassova Mulvaney of Kirkland & Ellis report.

Drug price regulation in Brazil: Roche faces IP rights abuse claims

Brazil02-08-2016Anderson Ribeiro and Ricardo Campello

The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case.

Brexit and IP: business as usual, for now

EU, UK07-07-2016Claire Phipps-Jones

Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.

Freeing Africa from hunger

Kenya08-06-2016

Africa Harvest is working towards reducing hunger and poverty in some of the world’s poorest countries. Dr Florence Wambugu, founder of the organisation, tells LSIPR more about its work.

Biotech in Birmingham: Alta Innovations’ story

UK05-06-2016

Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR.

Showing 31 to 40 of 45 results

LSIPR